NASDAQ:ALZN Alzamend Neuro (ALZN) Stock Price, News & Analysis $2.96 -0.04 (-1.17%) Closing price 07/3/2025 03:25 PM EasternExtended Trading$2.96 0.00 (0.00%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Alzamend Neuro Stock (NASDAQ:ALZN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Alzamend Neuro alerts:Sign Up Key Stats Today's Range$2.90▼$3.0450-Day Range$2.90▼$6.1252-Week Range$2.75▼$135.54Volume89,378 shsAverage Volume464,647 shsMarket Capitalization$2.37 millionP/E RatioN/ADividend YieldN/APrice Target$180.00Consensus RatingBuy Company Overview Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia. Read More Alzamend Neuro Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreALZN MarketRank™: Alzamend Neuro scored higher than 53% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAlzamend Neuro has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAlzamend Neuro has received no research coverage in the past 90 days.Read more about Alzamend Neuro's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Alzamend Neuro are expected to decrease in the coming year, from ($1.68) to ($1.71) per share.Read more about Alzamend Neuro's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted17.46% of the float of Alzamend Neuro has been sold short.Short Interest Ratio / Days to CoverAlzamend Neuro has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alzamend Neuro has recently decreased by 80.71%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAlzamend Neuro does not currently pay a dividend.Dividend GrowthAlzamend Neuro does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted17.46% of the float of Alzamend Neuro has been sold short.Short Interest Ratio / Days to CoverAlzamend Neuro has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alzamend Neuro has recently decreased by 80.71%, indicating that investor sentiment is improving significantly. News and Social Media1.1 / 5News SentimentN/A Search Interest13 people have searched for ALZN on MarketBeat in the last 30 days. This is an increase of 8% compared to the previous 30 days.MarketBeat Follows5 people have added Alzamend Neuro to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Alzamend Neuro insiders have not sold or bought any company stock.Percentage Held by Insiders30.21% of the stock of Alzamend Neuro is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions49.61% of the stock of Alzamend Neuro is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Alzamend Neuro's insider trading history. Receive ALZN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alzamend Neuro and its competitors with MarketBeat's FREE daily newsletter. Email Address ALZN Stock News HeadlinesAlzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of ScheduleJune 16, 2025 | globenewswire.comAlzamend Neuro Stock Rockets On Dosing Of First Human Patient With Lithium-Delivery System AL001 In Phase II Study: Retail’s ThrilledMay 29, 2025 | msn.comElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.July 4 at 2:00 AM | Brownstone Research (Ad)Alzamend Neuro Stock Doubles After Dosing of First Patient in Clinical TrialMay 29, 2025 | marketwatch.comAlzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General HospitalMay 29, 2025 | globenewswire.comAlzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General HospitalMay 19, 2025 | globenewswire.comAlzamend Neuro, Inc.: Alzamend Neuro Announces Reverse Stock SplitMay 16, 2025 | finanznachrichten.deAlzamend Neuro, Inc.May 15, 2025 | cnn.comSee More Headlines ALZN Stock Analysis - Frequently Asked Questions How have ALZN shares performed this year? Alzamend Neuro's stock was trading at $10.44 at the beginning of the year. Since then, ALZN shares have decreased by 71.6% and is now trading at $2.9650. How were Alzamend Neuro's earnings last quarter? Alzamend Neuro, Inc. (NASDAQ:ALZN) posted its quarterly earnings data on Monday, March, 10th. The company reported ($1.71) EPS for the quarter, topping analysts' consensus estimates of ($2.61) by $0.90. When did Alzamend Neuro's stock split? Alzamend Neuro's stock reverse split on the morning of Tuesday, July 16th 2024.The 1-10 reverse split was announced on Tuesday, July 16th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Alzamend Neuro IPO? Alzamend Neuro (ALZN) raised $12 million in an IPO on Tuesday, June 15th 2021. The company issued 2,500,000 shares at a price of $5.00 per share. Spartan Capital Securities, LLC acted as the underwriter for the IPO and -- was co-manager. How do I buy shares of Alzamend Neuro? Shares of ALZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Alzamend Neuro own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alzamend Neuro investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), Predictive Oncology (POAI), AST SpaceMobile (ASTS), NIO (NIO) and Ford Motor (F). Company Calendar Last Earnings3/10/2025Today7/04/2025Next Earnings (Estimated)7/29/2025Fiscal Year End4/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ALZN CIK1677077 Webwww.alzamend.com Phone844-722-6303FaxN/AEmployees4Year FoundedN/APrice Target and Rating Average Stock Price Target$180.00 High Stock Price Target$180.00 Low Stock Price Target$180.00 Potential Upside/Downside+5,970.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$9.95 million Net MarginsN/A Pretax MarginN/A Return on Equity-497.73% Return on Assets-147.21% Debt Debt-to-Equity RatioN/A Current Ratio5.44 Quick Ratio5.44 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($31.66) per share Price / Book-0.09Miscellaneous Outstanding Shares801,000Free Float559,000Market Cap$2.37 million OptionableNo Data Beta-0.31 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:ALZN) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTop Picks for Trump’s Pro-Crypto AmericaMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredRevealed: NEW A.I. revolution (nobody is talking about)Nvidia's CEO says this is: "The next wave of A.I." We're at the cusp of a new "A.I. Upgrade" that is set to...Behind the Markets | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alzamend Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alzamend Neuro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.